Figure 5.

Prothrombin time assay. The biological activity of the purified recombinant his-tagged FVII was evaluated by the prothrombin time test. A three-fold decrease in clotting time was observed when human FVII-depleted plasma was used in combination with human thromboplastin and the his-tagged recombinant FVII produced in this study. About a four-fold decrease in clotting time was observed when a commercially available preparation of recombinant FVII (NovoSeven), was tested. The experiment was performed in triplicate and the data are presented as mean ± SD.